WCLC 2025 - Posters & ePosters-EP.04.29 Tobacco-Related Atheromatous Disease as Eligibility Criteria for Lung Cancer Screening: A Prospective Evaluation

EP.04.29 Tobacco-Related Atheromatous Disease as Eligibility Criteria for Lung Cancer Screening: A Prospective Evaluation

Back to course

Pdf Summary

This prospective study evaluated lung cancer (LC) screening eligibility using tobacco-related atheromatous disease as a criterion, alongside age and tobacco consumption history. Conducted between November 2019 and May 2024, the study involved 505 participants aged 45 to 80 with a history of at least 10 years of daily smoking and documented tobacco-related atheromatous disease. The study aimed to report LC prevalence after the first round of screening and compare eligibility rates against established trials—NLST and NELSON.<br /><br />Exclusion criteria included symptomatic lung cancer, pulmonary nodules follow-up, fibrosis, pulmonary hypertension, severe cardiac/respiratory failure, and active pulmonary infections. The cohort was predominantly male (80.8%), average age 63 years, with notable rates of hypertension (59.9%), dyslipidemia (60.6%), COPD (18.4%), and coronary artery disease (66.3%).<br /><br />Results showed a lung cancer prevalence of 2.99% [1.81-4.90], which was significantly higher than the NLST (2.91%) and comparable to the NELSON trial (3.37%). Eligibility rates within the cohort were 59% for NELSON criteria and 50.8% for NLST. Most detected cancers were early stage (Stage I: 73.3%), with 80% of cases amenable to curative surgery; surgery was safe with no mortality or severe adverse events reported. Histology predominantly featured adenocarcinoma (10/15 cases). Additionally, smoking cessation was achieved in 14.5% of participants.<br /><br />The study concluded that incorporating tobacco-related atheromatous disease as an eligibility criterion improves lung cancer detection rates compared to traditional screening guidelines and supports its use for lung cancer screening programs. Early-stage detection and safe curative interventions were highlighted as key benefits.

Asset Subtitle

Elsa Armand

Meta Tag

Speaker Elsa Armand

Topic Screening and Early Detection

Keywords

lung cancer screening

tobacco-related atheromatous disease

NLST trial

NELSON trial

lung cancer prevalence

screening eligibility criteria

early-stage lung cancer

adenocarcinoma

curative lung surgery

smoking cessation